Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Hormone, Biologic therapy.

CRCUM-Universite de Montreal, Montreal, Quebec, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:5City/State/Province:Montreal, Quebec
Treatments:Chemotherapy, Hormone, Biologic therapyHospital:CRCUM-Universite de Montreal
Drugs:Journal:Link
Date:Sep 2011

Description:

Patients:
This study involved men with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Patients were divided into two separate treatment groups. Group A consisted of 20 patients with a median age of 68 years, while group B had 22 patients with a median age of 61 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel, the steroid hormone prednisone, and the biologic therapy agent called custirsen. Custirsen is classified as an antisense oligonucleotide and stops the production of an anti-cell death protein (clusterin).

Patients in group B were treated with the chemotherapy agent mitoxantrone, the steroid hormone prednisone, and the biologic therapy agent called custirsen.

Toxicities:
The most severe toxicities in group A were of grade 4. Grade 3-4 adverse events included fatigue, lymphopenia, and infection.

There were two treatment-related deaths in group B due to infection and heart attack. Grade 3-4 lymphopenia, fatigue, and weakness were also reported.

Results:
The median overall survival rates for groups A and B were 15.8 and 11.5 months, respectively.

Support:
This study was partially supported by Sanofi Aventis Pharmaceuticals.

Correspondence: Dr. Fred Saad; email: [email protected]



Back